Does the site of a Malignant melanoma predict the likelihood of distant metastases


Does the site of a Malignant melanoma predict the likelihood of distant metastases


Mohammed Al Abadie1, Khaleeq-Ur Rehman1, Mohammed Al-Rubaye1, Faris Oumeish1, Veena Shinde1, Abigail Pugh1, Dina Al Abadie2

1Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom; 2Department of Health Promotion and Public Health, University of West London, London, United Kingdom.


Introduction: Malignant melanoma is a lethal skin cancer which is on the rise despite increasing education on sun awareness. It is most common in young Caucasian individuals however any age or ethnicity can be affected.

Discussion: There are four main types of malignant melanoma which include superficial spreading MM (most common), Nodular (most lethal), Acral lentignous melanoma and Lentigo maligna melanoma. Once it has metastasized the prognosis is poor but new treatments are giving us much better outcomes.

Aim: The main aim of this study is to identify which MMs are most likely to metastasize based on the location with the two main groups being above neck and below neck.

Methods and results: forty-five patients were included in the study, 37 were below neck and 8 were above neck. Out of the 37 below neck MM patients, none had distant metastases , but 25% of the above neck MM patients had distant metastases.

Conclusion: This small study has demonstrated that above neck malignant melanoma is more likely to metastasize than below neck malignant melanoma despite advanced Tumor scores in the below neck subgroup.


Keywords: MM (malignant melanoma), SLNB (sentinel lymph node biopsy), metastasis


Free Full-text PDF


How to cite this article:
Mohammed Al Abadie, Khaleeq-Ur Rehman, Mohammed Al-Rubaye, Faris Oumeish, Veena Shinde, Abigail Pugh, Dina Al Abadie. Does the site of a Malignant melanoma predict the likelihood of distant metastases. American Journal of Dermatological Research and Reviews, 2020, 3:22. DOI: 10.28933/ajodrr-2020-01-3005


References:

1. Swetter, SM., Clarke, CA., Hurley S. Continuous increase in melanoma incidence across all socioeconomic status groups in California. J Invest dermatol. 2017. Nov; 137(11): 2282-2290.
2. Mun, Goo-Hyon. Management of malignant melanoma. Arch of plast surg. 2012 Sep ; 39(5): 565-574.
3. Brugnara S., Sicher M., Bonandine EM., et al. Treatment with combined dabrafenib and trametenib in BRAFV600E mutated metastatic melanoma: a case of long term complete response after treatment cessation. Drugs context 2018. Feb 15 7: 212525.
4. Yuxen, L., Saeed Sheikh, M., Melanoma molecular pathogenesis and therapeutic management. Mol Cell Pharmacol. 2014; 6(3): 228.
5. J. E. Gershenwald, C. M. Balch, S. J. Soong, and J. F. Thompson, “Prognostic factors and natural history of melanoma,” in Cutaneous Melanoma, C. M. Balch, A. N. Houghton, A. J. Sober, S. J. Soong, M. B. Atkins, and J. F. Thompson, Eds., pp. 35–64, Quality Medical Publishing, St. Louis, Mo, USA, 5th Edition, 2009.
6. Crowley, N.J.; Seigler, H.F. Late recurrence of malignant melanoma. Analysis of 168 patients. Ann. Surg. 1990, 212, 173-177.
7. Nathanson, S.D. Insights into the mechanisms of lymph node metastasis. Cancer 2003, 98, 413-423.
8. Harpole, D.H., Jr.; Johnson, C.M.; Wolfe, W.G.; George, S.L.; Seigler, H.F. Analysis of 945 cases of pulmonary metastatic melanoma. J. Thorac. Cardiovasc. Surg. 1992, 103, 743-748; discussion 748-750.
9. Platta, C.S.; Khuntia, D.; Mehta, M.P.; Suh, J.H. Current treatment strategies for brain metastasis and complications from therapeutic techniques: A review of current literature. Am. J. Clin. Oncol. 2010, 33, 398-407.
10. Balch, C.M.; Houghton, A.N.; Sober, A.J.; Soong, S. Cutaneous Melanoma, 4th edition; Quality Medical Publishing: St. Louis, MO, USA, 2003.
11. Taube, J.M.; Begum, S.; Shi, C.; Eshleman, J.R.; Westra, W.H. Benign nodal nevi frequently harbor the activating V600E Braf mutation. Am. J. Surg. Pathol. 2009, 33, 568-571.